Papillary thyroid cancer favors lymphatic spread both within the thyroid gland and to the cervical lymph nodes. Hematogenous spread rarely occurs in the lung, bones and brain. We report a case where metastatic nodules from papillary thyroid cancer were seen in the right aryepiglottic fold (supraglottis) and lateral wall of hypopharynx, an extremely rare event.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00405-012-2149-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Relationship between Cathepsins and Papillary Thyroid Carcinoma: A Mendelian Randomization Study.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Vascular and Thyroid Surgery, Affiliated Hospital of Guangdong Medical University, Guangdong, China.
Background: Papillary Thyroid Carcinoma (PTC) is the most common thyroid cancer, with an etiology and progression that are not fully understood. Research suggests a link between cathepsins and PTC, but the causal nature of this link is unclear. This study uses Mendelian Randomization (MR) to investigate if cathepsins causally influence PTC risk.
View Article and Find Full Text PDFALKBH5, an m6A demethylase, attenuates tumor growth and inhibits metastasis in papillary thyroid carcinoma.
Sci Rep
January 2025
Department of Endocrinology, The Second Affiliated Hospital of Fujian Medical University, No. 950 Donghai Street, Fengze District, Quanzhou, 362000, Fujian, China.
The significance of ALKBH5 in erasing mRNA methylation in mRNA biogenesis, decay, and translation control has emerged as a prominent research focus. Additionally, ALKBH5 is associated with the development of numerous human cancers. However, it remains unclear whether ALKBH5 regulates the growth and metastasis of papillary thyroid carcinoma (PTC).
View Article and Find Full Text PDFResearch progress in deubiquitinase OTUD3.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
August 2024
School of Economics and Management, Beijing Forestry University, Beijing 100083, China.
OTU domain-containing protein 3 (OTUD3) is a crucial deubiquitinase that exhibits significant expression differences across various disease models. OTUD3 plays a role in regulating biological functions such as apoptosis, inflammatory responses, cell cycle, proliferation, and invasion in different cell types. By deubiquitinating key substrate proteins, OTUD3 is involved in essential physiological and pathological processes, including innate antiviral immunity, neural development, neurodegenerative diseases, and cancer.
View Article and Find Full Text PDFInfluence of Body Mass Index on the Clinicopathological Features of Papillary Thyroid Carcinoma in a Chinese Population.
Metab Syndr Relat Disord
January 2025
NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, China.
Previous studies suggested a relationship between obesity and a high risk of thyroid cancer. However, the association between high body mass index (BMI) and the aggressiveness of papillary thyroid carcinoma (PTC) is controversial. In this study, we aimed to investigate the impact of excess BMI on histopathologic aggressiveness of PTC in a Chinese population.
View Article and Find Full Text PDFLong noncoding RNA FAM111A-DT promotes aggressiveness of papillary thyroid cancer via activating NF-κB signaling.
J Endocrinol Invest
January 2025
Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Purpose: Long noncoding RNAs (lncRNAs) play crucial regulatory roles in the tumorigenesis and progression of various cancers. However, the functional roles of lncRNAs in papillary thyroid cancer (PTC) remain unclear. In this study, we investigated the functional role of the lncRNA FAM111A-DT in PTC progression and the underlying mechanisms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!